Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVT001 in New-Onset Type 1 Diabetes
NCT03895996Phase 2Completed
- Sponsor
- Avotres Inc.
- Start
- Jun 2019
- Primary completion
- May 2022
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing AVT001 with Placebo (2 arms). Primary endpoints: Treatment-emergent Adverse Events at Day 150, Severity of Local i.v.-Site Reactions and 4 more. Started Jun 2019; status: completed.
02
Drugs
AVT001
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03895996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03895996.